Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

1.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
2.

Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study.

Shirinsky IV, Shirinsky VS.

Rheumatol Int. 2014 May;34(5):613-6. doi: 10.1007/s00296-013-2766-4. Epub 2013 Apr 26.

PMID:
23620259
3.

The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.

Shirinsky I, Polovnikova O, Kalinovskaya N, Shirinsky V.

Rheumatol Int. 2013 Dec;33(12):3045-8. doi: 10.1007/s00296-012-2613-z. Epub 2012 Dec 23.

PMID:
23263548
4.

Targeting Nuclear Hormone Receptors: PPARĪ± Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis.

Shirinsky IV, Shirinsky VS.

Int J Rheumatol. 2011;2011:937843. doi: 10.1155/2011/937843. Epub 2011 Jun 21.

5.

Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study.

Keystone EC, Shirinsky VS, Simon LS, Pedder S, Hewitt LA; CH-1504 Study Group.

J Rheumatol. 2011 Sep;38(9):1875-83. doi: 10.3899/jrheum.101038. Epub 2011 Jul 1.

PMID:
21724705
6.

Kinase-related protein/telokin inhibits Ca2+-independent contraction in Triton-skinned guinea pig taenia coli.

Shcherbakova OV, Serebryanaya DV, Postnikov AB, Schroeter MM, Zittrich S, Noegel AA, Shirinsky VP, Vorotnikov AV, Pfitzer G.

Biochem J. 2010 Jul 15;429(2):291-302. doi: 10.1042/BJ20090819.

7.

Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment.

Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA, Shirinsky VS.

Scand J Rheumatol. 2009 Jan-Feb;38(1):23-7. doi: 10.1080/03009740802363776.

PMID:
18830905
8.

Efficacy of simvastatin in plaque psoriasis: A pilot study.

Shirinsky IV, Shirinsky VS.

J Am Acad Dermatol. 2007 Sep;57(3):529-31. No abstract available.

PMID:
17707157
9.

Myosin light chain kinase colocalizes with nonmuscle myosin IIB in myofibril precursors and sarcomeric Z-lines of cardiomyocytes.

Dudnakova TV, Stepanova OV, Dergilev KV, Chadin AV, Shekhonin BV, Watterson DM, Shirinsky VP.

Cell Motil Cytoskeleton. 2006 Jul;63(7):375-83.

PMID:
16634081
10.

Novel phosphospecific antibodies for monitoring phosphorylation of proteins encoded by the myosin light chain kinase genetic locus.

Khapchaev AY, Krymsky MA, Sidorova MV, Bespalova ZhD, Wang CL, Shirinsky VP, Vorotnikov AV.

Biochemistry (Mosc). 2004 Jul;69(7):789-98.

PMID:
15310280
11.

Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domain.

Kudryashov DS, Stepanova OV, Vilitkevich EL, Nikonenko TA, Nadezhdina ES, Shanina NA, Lukas TJ, Van Eldik LJ, Watterson DM, Shirinsky VP.

Exp Cell Res. 2004 Aug 15;298(2):407-17.

PMID:
15265689
12.

Alterations in myocardial ultrastructure and protein expression after a single injection of isoproterenol.

Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VI.

Mol Cell Biochem. 2003 Oct;252(1-2):173-81.

PMID:
14577591
13.

Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment.

Wainwright MS, Rossi J, Schavocky J, Crawford S, Steinhorn D, Velentza AV, Zasadzki M, Shirinsky V, Jia Y, Haiech J, Van Eldik LJ, Watterson DM.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):6233-8. Epub 2003 May 2.

14.

Alterations in myocardial cytoskeletal and regulatory protein expression following a single Doxorubicin injection.

Dudnakova TV, Lakomkin VL, Tsyplenkova VG, Shekhonin BV, Shirinsky VP, Kapelko VI.

J Cardiovasc Pharmacol. 2003 May;41(5):788-94.

PMID:
12717111
15.

Social Stress Disorders and Immunity.

Shirinsky IV, Shirinsky VS.

Russ J Immunol. 2001 Jul;6(2):207-214.

PMID:
12687222
16.

High-Dose Immunosupression and Stem Cell Transplantation in Severe Autoimmune Diseases.

Lisukov IA, Kulagin AD, Sizikova SA, Kruchkova IV, Gilevich AV, Chernykh HR, Leplina OY, Konenkova LP, Zonova EV, Shirinsky VS.

Russ J Immunol. 2001 Jul;6(2):187-192.

PMID:
12687219
17.

Smooth muscle myosin filament assembly under control of a kinase-related protein (KRP) and caldesmon.

Kudryashov DS, Vorotnikov AV, Dudnakova TV, Stepanova OV, Lukas TJ, Sellers JR, Watterson DM, Shirinsky VP.

J Muscle Res Cell Motil. 2002;23(4):341-51.

PMID:
12630709
18.

Signal transduction and protein phosphorylation in smooth muscle contraction.

Vorotnikov AV, Krymsky MA, Shirinsky VP.

Biochemistry (Mosc). 2002 Dec;67(12):1309-28. Review.

PMID:
12600261
19.

Phosphorylation of kinase-related protein (telokin) in tonic and phasic smooth muscles.

Krymsky MA, Kudryashov DS, Shirinsky VP, Lukas TJ, Watterson DM, Vorotnikov AV.

J Muscle Res Cell Motil. 2001;22(5):425-37.

PMID:
11964068
20.

Actomyosin cross-linking by caldesmon in non-muscle cells.

Goncharova EA, Shirinsky VP, Shevelev AY, Marston SB, Vorotnikov AV.

FEBS Lett. 2001 May 25;497(2-3):113-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk